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Choroidal melanoma is the most common primary 
intraocular tumor in adults [1]. The 15-year risk of metastatic 
disease is approximately 50%, with the median survival 
after metastasis less than 6 months [2,3]. The risk factors 
for metastatic disease include the clinical, histologic, and 
cytogenetic characteristics of the primary tumor. The most 
robust predictor of metastatic disease to date is the loss of one 
copy of chromosome 3 [4].
Because of the strong correlation between chromosome 
3 status and metastatic outcome, intraoperative fine needle 
aspiration biopsy (FNAB) may be performed during brachy-
therapy or immediately following enucleation. This method 
is reliable and safe for obtaining representative samples of 
tumor tissue to provide molecular prognosis [5-7].
Previous studies have established that, among uveal 
melanomas positive for monosomy 3, this cytogenetic 
alteration may not be present in every tumor cell [8-14]. The 
heterogeneity of monosomy 3 in uveal melanomas raises the 
question of what percentage of monosomy 3 in the tumor 
is necessary to constitute a poor outcome. A recent review 
reported that the cutoff point used for determining the pres-
ence of monosomy 3 varies widely in the literature, from 
5% to as high as 60% [15]. There is currently no accepted 
threshold value for labeling a specimen monosomy 3 positive. 
However, Bronkhorst et al. [8] recently reported that a mono-
somy 3 cutoff value of 30% was the most robust predictor of 
metastasis-related death, although cutoff values of 5% and 
50% also predicted poor prognosis. Most recently, van den 
Bosch et al. [16] reported on the heterogeneity of monosomy 
3 in sections of enucleated specimens. Tumors were stratified 
into three groups based on the percentage of monosomy 3, and 
prognosis was incrementally worse with higher percentages 
of monosomy 3. Although one might extrapolate from this 
that the situation in a fine needle biopsy would yield a similar 
result regarding metastasis, no data to date have supported 
an increased risk of metastasis with a higher percentage of 
monosomy 3 in a fine needle biopsy.
Although larger tumor size correlates with the presence 
of monosomy 3 [17,18], the relationship between tumor size 
and percentage of monosomy 3 in the tumor has not been 
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Purpose: To report on the heterogeneity of monosomy 3 in a fine needle aspiration biopsy obtained transsclerally from 
choroidal melanoma for prognosis.
Methods: All clinical records for patients who had been diagnosed with choroidal melanoma and underwent iodine-125 
plaque brachytherapy with intraoperative transscleral fine needle aspiration biopsy from January 2005 to August 20, 
2011, and who had a positive result for monosomy 3 according to fluorescence in situ hybridization as reported by clinical 
cytogenetics testing were collected. Patient age and sex, total number of cells evaluated and number of cells positive for 
monosomy 3, tumor size, and metastatic outcome were recorded for each patient.
Results: A positive result for monosomy 3 was reported in 93 patients who underwent transscleral fine needle aspiration 
biopsy. Two patients were lost to follow-up immediately post-operatively, and the remaining 91 patients were included 
in this study. The mean number of cells evaluated in the biopsy was 273 (range 28 to 520). The mean percentage of cells 
positive for monosomy 3 was 62.9% (range 4.7%–100%). The mean tumor height was 5.91 mm (range 1.99 to 10.85 mm). 
Larger tumors were associated with a higher percentage of cells positive for monosomy 3. During the average follow-up 
interval of 28.9 months (range 3–76 months), choroidal melanoma metastasis developed in 18 (20%) patients. Patients 
whose tumors had 1%–33% of cells positive for monosomy 3 had a significantly lower risk of metastasis-related death 
compared to patients whose tumors harbored a higher percentage of monosomy 3 (p=0.04).
Conclusions: Cytogenetic heterogeneity of fluorescent in situ hybridization for monosomy 3 exists in a biopsy sample. 
Larger tumors were more likely to have a higher percentage of monosomy 3 positive cells in the sample. Furthermore, 
patients whose tumors had more than 33% of cells positive for monosomy 3 had a poorer prognosis than patients whose 
tumors had lower percentages of monosomy 3.
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established. We hypothesized that larger tumors may have 
a higher percentage of cells with monosomy 3, because they 
are more advanced and the cells may therefore have had more 
opportunity to lose a copy of chromosome 3.
Most previous studies on the prognostic value of mono-
somy 3 in uveal melanoma used tumor samples obtained 
during enucleation [4,8,16]. Although this procedure has 
yielded important information on the poor prognosis of 
tumors positive for monosomy 3, this procedure is not directly 
applicable to patients who have monosomy 3 positive tumors 
discovered with FNAB during brachytherapy, as patients 
selected for brachytherapy generally have smaller and less 
advanced tumors. We present data on the prognostic value of 
monosomy 3 in patients undergoing globe-sparing therapy.
We reviewed the charts of patients with uveal melanomas 
who underwent brachytherapy with transscleral FNAB and 
were positive for monosomy 3 according to fluorescence in 
situ hybridization (FISH). Based on these data, we evaluated 
whether there was an association between 1) percentage of 
monosomy 3 and metastatic disease and 2) tumor height and 
percentage of monosomy 3.
METHODS
The study was performed in accordance with the U.S. Health 
Insurance Portability and Accountability Act (HIPAA) 
of 1996 and was approved by the Office of the Human 
Research Protection Program (Institutional Review Board) 
of the University of California, Los Angeles. The records of 
all patients who gave informed consent and had a clinical 
diagnosis of choroidal melanoma who underwent intraop-
erative transscleral FNAB during plaque brachytherapy at 
the Jules Stein Eye Institute, University of California, Los 
Angeles, between January 1, 2005, and August 20, 2011, 
were reviewed. All patients whose tumors were positive for 
monosomy 3 according to FISH were included in this study, 
excluding patients who were lost to follow-up immediately 
post-operatively.
Diagnosis of choroidal melanoma was established 
with comprehensive ophthalmic examination, ultrasonog-
raphy, and fluorescein angiography. Systemic evaluation 
by an oncologist or internal medicine specialist revealed no 
evidence of melanoma metastasis or other active primary 
cancer, and psychological support was offered by a clinical 
psychologist or social worker with expertise in choroidal 
melanoma [19].
Iodine-125 plaque surgery with FNAB was performed 
by a single surgeon (TAM). Details of FNAB and radioactive 
plaque placement have been described elsewhere [7,19-22]. 
Briefly, FNAB was performed with a 30-gauge needle via a 
tangential transscleral approach. Examination with binocular 
indirect ophthalmoscopy was performed immediately after 
FNAB, and the plaque was sutured in place. Optimal plaque 
position was achieved with intraoperative ultrasonography 
[23].
Biopsy specimens were processed for cytopathologic 
analysis and cytogenetic analysis as described in a previous 
report [22]. In general, the first biopsy specimen was imme-
diately smeared on glass slides, fixed in ethanol, and stained 
with hematoxylin–eosin. A sample from an additional biopsy 
and/or residual material in the initial needle was rinsed in 
culture medium for cytogenetic analysis. Indeterminate 
samples were later tested with immunohistochemistry for 
the human melanoma black-45 antibody.
Chromosome 3 status was evaluated at the University of 
California, Los Angeles Clinical Cytogenetics Laboratory, a 
standardized CLIA-approved laboratory with a cytogeneticist 
experienced in interpreting and reporting FISH results for 
uveal melanoma. Cells collected for cytogenetic analysis were 
gently spun down in a sterile conical tube and resuspended in 
Rosewell Park Memorial Institute 1640 (RPMI-1640) media 
(Gibco [Invitrogen], Carlsbad, CA) supplemented with anti-
biotics and 10% bovine serum (Irvine Scientific, Santa Ana, 
CA). The cultures were observed for appropriate growth and 
mitotic activity, and cytogenetic studies were performed on 
short-term cultures prepared according to standard proto-
cols. For FISH analysis, a directly labeled centromeric probe 
specific for chromosome 3, CEP-3 Spectrum Orange (Vysis, 
Downers Grove, IL), was used to assess monosomy or disomy. 
This probe was hybridized to fixed cultured cells following 
the manufacturer’s protocol (Abbott-Vysis, Des Plaines, IL). 
Hybridization signals were counted by hand in nonoverlap-
ping nuclei of cells under a fluorescence microscope (Axio-
phot, Carl Zeiss Mikroskopie, Jena, Germany) equipped 
with a triple filter (diamino-2-phenylindole dihydrochloride/
fluorescein isothiocyanate/Texas Red). When any cells were 
found to contain only one copy of chromosome 3, the sample 
was considered positive for monosomy 3.
Patients were evaluated post-operatively according to 
a standardized schedule. Follow-up visits were scheduled 
at 1 week, 1 month, 3 months, and 6 months after brachy-
therapy, and every 6 months thereafter. Starting at 3 months, 
A- and B-scan ultrasonography was performed at each visit 
to evaluate tumor response to brachytherapy. Patients were 
also instructed to undergo biannual systemic evaluation for 
metastatic disease, which included liver function testing and 
abdominal imaging with ultrasound, computed tomography, 
magnetic resonance imaging, or combined positron emission 
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tomography/computed tomography at a minimum of once per 
year. The patient’s primary care physician or medical oncolo-
gist was contacted twice per year to reinforce the investiga-
tions for systemic surveillance.
Patient charts were retrospectively reviewed, and the 
following data were collected: demographic information, 
tumor parameters, date of brachytherapy surgery, FNAB 
cytopathology, choroidal melanoma metastatic disease and/
or tumor-related death, monosomy 3 status according to 
FISH analysis, and last date of follow-up. The online Social 
Security Death Index was searched using patients’ names 
and birthdates to identify and confirm deceased patients. In 
the case of patients who were found to be deceased using 
this index, the patients’ families were contacted to determine 
whether the cause of death was metastatic disease. Length of 
follow-up was determined by calculating the number of days 
between the date of the brachytherapy surgery and the last 
date of follow-up. Patient data were tabulated using Excel 
(Microsoft Office Excel 2003; Microsoft, Redmond, WA) 
and analyzed using Excel and MedCalc (MedCalc version 
12.5.0.0, MedCalc Software bvba, Ostend, Belgium).
The Pearson correlation coefficient was used to evaluate 
the relationship between the percentage of monosomy 3 and 
tumor height. Kaplan–Meier survival curves were generated 
for analyzing metastasis-related survival by using the log-
rank test. A p value of less than 0.05 was considered statisti-
cally significant.
RESULTS
Between January 2005 and September 2011, 93 patients with 
uveal melanoma who had undergone tumor treatment with 
iodine-125 plaque brachytherapy were identified whose FISH 
result from FNAB was positive for monosomy 3. Two patients 
were lost to follow-up immediately post-operatively and were 
excluded from this study. The patient and tumor characteris-
tics for the remaining 91 cases are shown in Table 1, stratified 
by percentage of monosomy 3. Overall, the mean patient age 
was 64.7 years (range 20 to 91). Forty-nine patients were 
male, and 42 patients were female. The mean tumor height 
was 5.91 mm (range 1.99 to 10.85 mm). The mean number 
of cells evaluated for FISH analysis was 273 (range 28 to 
520). The mean percentage of cells with monosomy 3 was 
62.9% (range 4.7% to 100%). Eighteen patients (20%) devel-
oped metastatic disease over a mean follow-up period of 28.9 
months (range 3 to 76 months).
The distribution of the percentage of cells positive for 
monosomy 3 per patient biopsy sample is shown in Figure 
1. The relationship between tumor height and percentage of 
monosomy 3 per biopsy sample is shown in Figure 2. There 
was a significant positive correlation between tumor height 
and percentage of monosomy 3 (p=0.02).
The Kaplan–Meier survival curve among patients with 
1%–33%, 33%–66%, and 66%–100% of monosomy 3 positive 
cells is shown in Figure 3. There was a significantly lower 
metastasis-free survival rate in patients who had more than 
33% cells positive for monosomy 3 versus patients who had 
fewer than 33% cells positive for monosomy 3. However, 
there was no significant difference in the metastasis-free 
survival rate between patients who had 33%–66% cells posi-
tive for monosomy 3 and patients who had 66%–100% cells 
positive for monosomy 3.
DISCUSSION
We report on the heterogeneous distribution of monosomy 
3 in 91 patients with uveal melanoma who underwent trans-
scleral FNAB during brachytherapy and were positive for 
monosomy 3 according to FISH. Percentage of monosomy 
3 ranged between 4.7% and 100%, with a mean of 62.9%, 
which is consistent with previous reports of variation in 
chromosome 3 copy number in uveal melanomas [8-14]. 
Overall, 18 patients (20%) developed metastatic disease 
during a mean follow-up interval of 28.9 months. Moreover, 
we found a significant association between the percentage of 
monosomy 3 in a biopsy sample and the development of meta-
static disease in the patient. The metastasis-free survival rate 
significantly decreased in patients whose tumors had more 
than 33% of cells positive for monosomy 3. In addition, there 
was a significant positive correlation between tumor height 
and percentage of monosomy 3.
Our study also has important prognostic implications 
for patients undergoing globe-sparing therapy. The majority 
of previous reports on the prognostic value of monosomy 3 
focused on samples obtained during enucleation [4]. Because 
tumors that are selected for enucleation are generally larger 
and more advanced than those treated with brachytherapy, the 
prognosis for patients with monosomy 3 positive tumors that 
undergo enucleation may be different from that for patients 
with monosomy 3 tumors who are candidates for brachy-
therapy. We report an overall rate of metastasis of 20% over 
a mean follow-up interval of 28.9 months. This is similar to 
the metastatic rate reported by Shields et al. [24] in a group of 
patients with uveal melanomas who underwent FNAB during 
brachytherapy. The FNAB specimens were analyzed with 
microsatellite analysis. Among 126 patients with complete 
monosomy 3, the cumulative probability of metastasis was 
8.9% at 24 months and 24.0% at 36 months. The minimum 
percentage of cells with only one copy of chromosome 3 
Molecular Vision 2013; 19:1892-1900 <http://www.molvis.org/molvis/v19/1892> © 2013 Molecular Vision 
1895
Ta
b
l
e
 1
. P
a
T
ie
n
T
 a
n
d
 T
u
m
o
r
 c
h
a
r
a
c
T
e
r
is
T
ic
s o
f 
91
 c
a
se
s o
f 
u
v
e
a
l
 m
e
l
a
n
o
m
a
 P
o
si
T
iv
e 
fo
r
 m
o
n
o
so
m
y
 3
 b
y
 f
is
h
 f
r
o
m
 T
r
a
n
ss
c
l
e
r
a
l
 f
n
a
b
.
Pe
rc
en
ta
ge
 o
f m
on
os
om
y 
3
1%
–3
3%
33
%
–6
6%
66
%
–1
00
%
O
ve
ra
ll
N
um
be
r o
f c
as
es
24
15
52
91
M
ea
n 
ag
e 
(ra
ng
e)
62
.8
 (2
0–
91
)
64
.3
 (2
9–
79
)
65
.7
 (3
9–
91
)
64
.7
 (2
0–
91
)
M
al
e/
Fe
m
al
e
15
/9
7/
8
27
/2
5
49
/4
2
M
ea
n 
tu
m
or
 h
ei
gh
t i
n 
m
m
 (r
an
ge
)
5.
2 
(2
.0
–1
0.
9)
5.
3 
(2
.3
–9
.0
)
6.
4 
(2
.0
–1
0.
8)
5.
91
 (1
.9
9–
10
.8
5)
N
um
be
r o
f t
um
or
s w
ith
 c
ili
ar
y 
bo
dy
 in
vo
lv
em
en
t
5 
(2
0.
8%
)
3 
(2
0%
)
16
 (3
0.
8%
)
24
 (2
6.
4%
)
M
ea
n 
nu
m
be
r o
f c
el
ls
 e
va
lu
at
ed
 (r
an
ge
)
28
2 
(8
3–
52
0)
26
5 
(4
8 
to
 4
10
)
27
1 
(2
8–
48
3)
27
3 
(2
8–
52
0)
N
um
be
r o
f p
at
ie
nt
s w
ith
 m
et
as
ta
si
s
1 
(4
.2
%
)
5 
(3
3.
3%
)
12
 (2
3.
1%
)
18
 (2
0%
)
M
ea
n 
fo
llo
w
-u
p 
in
 m
on
th
s (
ra
ng
e)
29
.2
 (3
–6
5)
21
.3
 (5
–5
5)
31
.6
 (3
–7
6)
28
.9
 (3
–7
6)
M
ea
n 
pe
rc
en
ta
ge
 o
f m
on
os
om
y 
3 
(ra
ng
e)
-
-
-
62
.9
%
 (4
.7
%
–1
00
%
)
Molecular Vision 2013; 19:1892-1900 <http://www.molvis.org/molvis/v19/1892> © 2013 Molecular Vision 
1896
necessary to categorize a tumor as monosomy 3 positive was 
not reported.
Our finding that a percentage of monosomy 3 above 33% 
is associated with significantly decreased metastasis-free 
survival is similar to the findings of Bronkhorst et al. [8], 
who performed karyotyping and FISH on cultured cells and 
FISH on isolated nuclei of enucleated specimens of primary 
uveal melanoma [8]. The authors found a range of percentages 
for monosomy 3 in the samples, and evaluated the predic-
tive value of monosomy 3 at various percentages for death 
by metastatic disease. Monosomy 3 positivity with a cutoff 
value of 30% was the most robust predictor of death due to 
metastasis. The authors also found that threshold monosomy 
3 percentages of 5% and 50%, in addition to 30%, were asso-
ciated with significantly increased risk of metastasis-related 
death.
Figure 1. Distribution of percentage 
of monosomy 3 in 91 patients with 
uveal melanoma positive for mono-
somy 3 according to fluorescence 
in situ hybridization of transscleral 
f ine needle aspiration biopsy 
specimens.
Figure 2. Relationship between 
tumor height and percentage of 
monosomy 3 in 91 patients with 
uveal melanoma positive for mono-
somy 3 according to fluorescence 
in situ hybridization of transscleral 
f ine needle aspiration biopsy 
specimens. 
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Our study differs from that of Bronkhorst et al. [8] in 
that we performed cytogenetic analysis on material obtained 
with FNAB during brachytherapy, rather than on enucleated 
specimens. Thus, our finding confirms the prognostic value 
of monosomy 3 with a cutoff of 30%–33% cells positive for 
monosomy 3 in FNAB specimens.
Van Den Bosch et al. [16] also evaluated the risk of 
metastasis-related death according to the percentage of mono-
somy 3 positive cells in patients who underwent enucleation 
with FISH analysis of tumor specimens [16]. In that study, 
risk of death from metastatic disease was analyzed with FISH 
among patients with tumor specimens harboring 0%–33%, 
33%–66%, and 66%–100% cells positive for monosomy 3. 
There was a statistically significant incrementally worse 
prognosis in patients with higher percentages of monosomy 3. 
In our study, we found, similar to Van Den Bosch et al. [16], 
that patients with 1%–33% cells positive for monosomy 3 had 
a significantly better metastasis-free survival rate. However, 
unlike Van Den Bosch et al. [16], we found no difference in 
prognosis between patients with 33%–66% cells positive for 
monosomy 3 and 66%–100% cells positive for monosomy 3. 
Our study results might have been skewed by a single outlier 
in the 33%–66% cells positive for monosomy 3 group who 
developed metastasis at 30 months (Figure 3). If our sample 
size were increased, we might find a statistically significant 
difference between the 33%–66% and 66%–100% groups, 
as did Van Den Bosch et al. [16]. Alternatively, the disparity 
between our results and those of Van Den Bosch et al. [16] 
may be due to the difference in specimen type (enucleation 
versus FNAB). Although FISH on FNAB samples has been 
shown to be an accurate predictor of the presence of mono-
somy 3 in uveal melanomas [5,6], the percentage of mono-
somy 3 according to FISH analysis of the FNAB samples 
may not represent the overall percentage of monosomy 3 cells 
in the tumor. Because FNAB samples only a portion of a 
heterogeneous tumor, the material obtained with FNAB is 
subject to sampling error. In addition, because FISH cannot 
be used to determine morphology and cell type, stromal cells 
such as leukocytes and endothelial cells may be included in 
FISH analysis. Because we lack the cytopathology of FISH 
samples, we cannot accurately identify the percentage of 
stromal cells in the FISH analysis.
Several studies have reported that larger tumors are more 
likely to be positive for monosomy 3 [25,26]. We evaluated 
the relationship between tumor height and percentage of cells 
positive for monosomy 3, and we found that larger tumors 
contained a significantly higher percentage of monosomy 3 
cells (Figure 2). We hypothesize that a larger, more advanced 
tumor might harbor a higher percentage of cells that had 
the opportunity to lose one copy of chromosome 3 [27,28]. 
However, smaller tumors may harbor a smaller percentage of 
Figure 3. Kaplan–Meier analysis 
of metastasis-free survival by 
percentage of monosomy 3. 
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monosomy 3 tumor cells due to having been in existence for 
a shorter period.
We found a bimodal distribution of percentage of mono-
somy 3 in the samples obtained with transscleral FNAB, with 
the greatest number of samples containing 80%–100% cells 
positive for monosomy 3 cells (Figure 1). This differs from 
the distribution of the percentage of monosomy 3 reported by 
Bronkhorst et al. [8] in enucleation specimens. The majority 
of the monosomy 3 cases reported in that study appeared to 
cluster near 50% [8]. The skewed distribution in our study 
may be related to sampling error. As discussed previously, 
the percentage of monosomy 3 in an FNAB sample may not 
correspond to the percentage of monosomy 3 in the entire 
tumor. In many cases, the monosomy 3 tumor cells may be 
physically clustered within a tumor such that when a positive 
sample is obtained, most of the cells are positive for mono-
somy 3.
Although monosomy 3 is the strongest cytogenetic 
predictor of metastatic disease, the mechanism by which loss 
of chromosome 3 increases risk of metastasis is unclear. The 
loss of one copy of chromosome 3 is associated with several 
factors known to portend poor prognosis in uveal melanoma, 
including ciliary body involvement, extraocular spread, 
larger basal tumor diameter, epithelioid cells, closed vascular 
loops, and high mitotic rate [25]. In addition, monosomy 3 
is associated with all other cytogenetic alterations in uveal 
melanomas, particularly abnormalities in chromosomes 1, 6, 
and 8, and the loss of chromosome 3 is thought to represent 
the initial cytogenetic aberration necessary for the develop-
ment of metastatic potential [27-29]. The specific gene or 
genes on chromosome 3 whose loss leads to the eventual 
ability to metastasize are only beginning to emerge. Muta-
tions in the BRCA1 associated protein-1 (ubiquitin carboxy-
terminal hydrolase) (BAP1) gene on chromosome 3p21 may 
be the reason melanoma cells lose one copy of chromosome 
3 [30,31]. Loss of heterozygosity studies have attempted to 
identify the location of a putative tumor suppressor on chro-
mosome 3, and have identified 3p25 as a region of common 
allelic loss [32]. Several candidate genes in this region may 
be important in uveal melanoma metastasis; however, other 
regions of chromosome 3 also show loss of heterozygosity in 
other studies [33]. Identifying the specific pathway by which 
monosomy 3 leads to uveal melanoma metastasis will guide 
future efforts to develop targeted therapies for this disease.
The strengths of this study include a single center with a 
standardized CLIA-approved laboratory with cytogeneticists 
experienced in interpreting and reporting the FISH results of 
uveal melanoma and an operator experienced in a consistent 
FNAB technique. Other strengths include excellent patient 
follow-up and reporting of metastasis. A relative weakness 
of the study is the relatively short follow-up period for evalu-
ating metastatic outcome. Uveal melanoma metastasis has 
been reported to occur more than 15 years after diagnosis 
of the primary tumor [3]. Further follow-up of this cohort is 
warranted.
In summary, we report the prognostic value, presence, 
and range of heterogeneity of monosomy 3 in an FNAB 
sample. Among a group of patients treated with globe-sparing 
therapy, the 29-month rate of metastatic disease was 20%. 
Larger tumors were associated with a significantly higher 
percentage of monosomy 3 in the FNAB sample. Moreover, 
our results indicate that tumors with more than 33% of cells 
positive for monosomy 3 in an FNAB specimen have a poor 
prognosis compared to tumors with lower percentages of 
monosomy 3. Our findings confirm results from enucleation 
specimens in FNAB samples and have implications for coun-
seling patients about their disease-related prognosis.
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